| Dr Olayinka Adenike Elesha, MD | |
|
1700 Medical Center Pkwy, Murfreesboro, TN 37129-2245 | |
| (615) 396-4694 | |
| (615) 396-6751 |
| Full Name | Dr Olayinka Adenike Elesha |
|---|---|
| Gender | Female |
| Speciality | Hospitalist |
| Experience | 25 Years |
| Location | 1700 Medical Center Pkwy, Murfreesboro, Tennessee |
| Accepts Medicare Assignments | May be. She may accept the Medicare-approved amount; you may be billed for more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1083887954 | NPI | - | NPPES |
| Q012384 | Medicaid | TN |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208M00000X | Hospitalist | 51853 (Tennessee) | Primary |
| 207R00000X | Internal Medicine | 51853 (Tennessee) | Secondary |
| Facility Name | Location | Facility Type |
|---|---|---|
| St Francis Hospital- Emory Healthcare | Columbus, GA | Hospital |
| Floyd Medical Center | Rome, GA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| 24 On Physicians Pc | 5698688141 | 250 |
| Southeastern Hospitalist Services Pc | 3476855420 | 276 |
News Archive
On Monday, President Donald Trump claimed that the World Health Organization (WHO) "admitted" he was correct that using lockdowns to control the spread of COVID-19 was more damaging than the illness.
TriReme Medical, a leading developer of innovative catheters and stents for the treatment of complex vascular disease, announced today the closing of a $17M Round D financing. The financing was led by Bio*One Capital, a subsidiary of Singapore based EDB Investments with strong support from current investors, Three Arch Partners and Adams Street Partners.
The Breast Cancer Research Foundation, announced its dedication of $58.6 million to breast cancer research today at its annual Symposium & Awards Luncheon. Totaling $47 million, the 2014-2015 annual grants, awarded to more than 220 physicians and scientists on six continents, continue to fuel BCRF's mission of advancing the world's most innovative research.
David Allan, Chairman and CEO of YM BioSciences Inc. and Thomas Wellner, President and CEO of Therapure Biopharma Inc. today announced the signing of an agreement under which Therapure Biopharma will provide fill and finish services for nimotuzumab, the humanized monoclonal antibody licensed to YM's majority-owned Canadian subsidiary, CIMYM BioSciences Inc., by the Centre of Molecular Immunology (CIM).
A diagnosis of prostate cancer raises the question for patients and their physicians as to how the tumor will behave. Will it grow quickly and aggressively and require continuous treatment, or slowly, allowing therapy and its risks to be safely delayed?
› Verified 7 days ago
| Entity Name | Cooperative Healthcare Services, Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1417979402 PECOS PAC ID: 9830093640 Enrollment ID: O20031124000222 |
News Archive
On Monday, President Donald Trump claimed that the World Health Organization (WHO) "admitted" he was correct that using lockdowns to control the spread of COVID-19 was more damaging than the illness.
TriReme Medical, a leading developer of innovative catheters and stents for the treatment of complex vascular disease, announced today the closing of a $17M Round D financing. The financing was led by Bio*One Capital, a subsidiary of Singapore based EDB Investments with strong support from current investors, Three Arch Partners and Adams Street Partners.
The Breast Cancer Research Foundation, announced its dedication of $58.6 million to breast cancer research today at its annual Symposium & Awards Luncheon. Totaling $47 million, the 2014-2015 annual grants, awarded to more than 220 physicians and scientists on six continents, continue to fuel BCRF's mission of advancing the world's most innovative research.
David Allan, Chairman and CEO of YM BioSciences Inc. and Thomas Wellner, President and CEO of Therapure Biopharma Inc. today announced the signing of an agreement under which Therapure Biopharma will provide fill and finish services for nimotuzumab, the humanized monoclonal antibody licensed to YM's majority-owned Canadian subsidiary, CIMYM BioSciences Inc., by the Centre of Molecular Immunology (CIM).
A diagnosis of prostate cancer raises the question for patients and their physicians as to how the tumor will behave. Will it grow quickly and aggressively and require continuous treatment, or slowly, allowing therapy and its risks to be safely delayed?
› Verified 7 days ago
| Entity Name | 24 On Physicians Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1912956251 PECOS PAC ID: 5698688141 Enrollment ID: O20031216000444 |
News Archive
On Monday, President Donald Trump claimed that the World Health Organization (WHO) "admitted" he was correct that using lockdowns to control the spread of COVID-19 was more damaging than the illness.
TriReme Medical, a leading developer of innovative catheters and stents for the treatment of complex vascular disease, announced today the closing of a $17M Round D financing. The financing was led by Bio*One Capital, a subsidiary of Singapore based EDB Investments with strong support from current investors, Three Arch Partners and Adams Street Partners.
The Breast Cancer Research Foundation, announced its dedication of $58.6 million to breast cancer research today at its annual Symposium & Awards Luncheon. Totaling $47 million, the 2014-2015 annual grants, awarded to more than 220 physicians and scientists on six continents, continue to fuel BCRF's mission of advancing the world's most innovative research.
David Allan, Chairman and CEO of YM BioSciences Inc. and Thomas Wellner, President and CEO of Therapure Biopharma Inc. today announced the signing of an agreement under which Therapure Biopharma will provide fill and finish services for nimotuzumab, the humanized monoclonal antibody licensed to YM's majority-owned Canadian subsidiary, CIMYM BioSciences Inc., by the Centre of Molecular Immunology (CIM).
A diagnosis of prostate cancer raises the question for patients and their physicians as to how the tumor will behave. Will it grow quickly and aggressively and require continuous treatment, or slowly, allowing therapy and its risks to be safely delayed?
› Verified 7 days ago
| Entity Name | Hamilton Medical Center, Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1528056066 PECOS PAC ID: 0446151179 Enrollment ID: O20040116000053 |
News Archive
On Monday, President Donald Trump claimed that the World Health Organization (WHO) "admitted" he was correct that using lockdowns to control the spread of COVID-19 was more damaging than the illness.
TriReme Medical, a leading developer of innovative catheters and stents for the treatment of complex vascular disease, announced today the closing of a $17M Round D financing. The financing was led by Bio*One Capital, a subsidiary of Singapore based EDB Investments with strong support from current investors, Three Arch Partners and Adams Street Partners.
The Breast Cancer Research Foundation, announced its dedication of $58.6 million to breast cancer research today at its annual Symposium & Awards Luncheon. Totaling $47 million, the 2014-2015 annual grants, awarded to more than 220 physicians and scientists on six continents, continue to fuel BCRF's mission of advancing the world's most innovative research.
David Allan, Chairman and CEO of YM BioSciences Inc. and Thomas Wellner, President and CEO of Therapure Biopharma Inc. today announced the signing of an agreement under which Therapure Biopharma will provide fill and finish services for nimotuzumab, the humanized monoclonal antibody licensed to YM's majority-owned Canadian subsidiary, CIMYM BioSciences Inc., by the Centre of Molecular Immunology (CIM).
A diagnosis of prostate cancer raises the question for patients and their physicians as to how the tumor will behave. Will it grow quickly and aggressively and require continuous treatment, or slowly, allowing therapy and its risks to be safely delayed?
› Verified 7 days ago
| Entity Name | Hospital Physician Services - Southeast Professional Corporation |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1760410385 PECOS PAC ID: 5597774554 Enrollment ID: O20060419000545 |
News Archive
On Monday, President Donald Trump claimed that the World Health Organization (WHO) "admitted" he was correct that using lockdowns to control the spread of COVID-19 was more damaging than the illness.
TriReme Medical, a leading developer of innovative catheters and stents for the treatment of complex vascular disease, announced today the closing of a $17M Round D financing. The financing was led by Bio*One Capital, a subsidiary of Singapore based EDB Investments with strong support from current investors, Three Arch Partners and Adams Street Partners.
The Breast Cancer Research Foundation, announced its dedication of $58.6 million to breast cancer research today at its annual Symposium & Awards Luncheon. Totaling $47 million, the 2014-2015 annual grants, awarded to more than 220 physicians and scientists on six continents, continue to fuel BCRF's mission of advancing the world's most innovative research.
David Allan, Chairman and CEO of YM BioSciences Inc. and Thomas Wellner, President and CEO of Therapure Biopharma Inc. today announced the signing of an agreement under which Therapure Biopharma will provide fill and finish services for nimotuzumab, the humanized monoclonal antibody licensed to YM's majority-owned Canadian subsidiary, CIMYM BioSciences Inc., by the Centre of Molecular Immunology (CIM).
A diagnosis of prostate cancer raises the question for patients and their physicians as to how the tumor will behave. Will it grow quickly and aggressively and require continuous treatment, or slowly, allowing therapy and its risks to be safely delayed?
› Verified 7 days ago
| Entity Name | Apogee Medical Group Georgia |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1629025143 PECOS PAC ID: 4587676945 Enrollment ID: O20060629000214 |
News Archive
On Monday, President Donald Trump claimed that the World Health Organization (WHO) "admitted" he was correct that using lockdowns to control the spread of COVID-19 was more damaging than the illness.
TriReme Medical, a leading developer of innovative catheters and stents for the treatment of complex vascular disease, announced today the closing of a $17M Round D financing. The financing was led by Bio*One Capital, a subsidiary of Singapore based EDB Investments with strong support from current investors, Three Arch Partners and Adams Street Partners.
The Breast Cancer Research Foundation, announced its dedication of $58.6 million to breast cancer research today at its annual Symposium & Awards Luncheon. Totaling $47 million, the 2014-2015 annual grants, awarded to more than 220 physicians and scientists on six continents, continue to fuel BCRF's mission of advancing the world's most innovative research.
David Allan, Chairman and CEO of YM BioSciences Inc. and Thomas Wellner, President and CEO of Therapure Biopharma Inc. today announced the signing of an agreement under which Therapure Biopharma will provide fill and finish services for nimotuzumab, the humanized monoclonal antibody licensed to YM's majority-owned Canadian subsidiary, CIMYM BioSciences Inc., by the Centre of Molecular Immunology (CIM).
A diagnosis of prostate cancer raises the question for patients and their physicians as to how the tumor will behave. Will it grow quickly and aggressively and require continuous treatment, or slowly, allowing therapy and its risks to be safely delayed?
› Verified 7 days ago
| Entity Name | Wellstar Medical Group, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1558664003 PECOS PAC ID: 6709065402 Enrollment ID: O20110127000374 |
News Archive
On Monday, President Donald Trump claimed that the World Health Organization (WHO) "admitted" he was correct that using lockdowns to control the spread of COVID-19 was more damaging than the illness.
TriReme Medical, a leading developer of innovative catheters and stents for the treatment of complex vascular disease, announced today the closing of a $17M Round D financing. The financing was led by Bio*One Capital, a subsidiary of Singapore based EDB Investments with strong support from current investors, Three Arch Partners and Adams Street Partners.
The Breast Cancer Research Foundation, announced its dedication of $58.6 million to breast cancer research today at its annual Symposium & Awards Luncheon. Totaling $47 million, the 2014-2015 annual grants, awarded to more than 220 physicians and scientists on six continents, continue to fuel BCRF's mission of advancing the world's most innovative research.
David Allan, Chairman and CEO of YM BioSciences Inc. and Thomas Wellner, President and CEO of Therapure Biopharma Inc. today announced the signing of an agreement under which Therapure Biopharma will provide fill and finish services for nimotuzumab, the humanized monoclonal antibody licensed to YM's majority-owned Canadian subsidiary, CIMYM BioSciences Inc., by the Centre of Molecular Immunology (CIM).
A diagnosis of prostate cancer raises the question for patients and their physicians as to how the tumor will behave. Will it grow quickly and aggressively and require continuous treatment, or slowly, allowing therapy and its risks to be safely delayed?
› Verified 7 days ago
| Entity Name | Southeastern Hospitalist Services Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1003280108 PECOS PAC ID: 3476855420 Enrollment ID: O20160107001140 |
News Archive
On Monday, President Donald Trump claimed that the World Health Organization (WHO) "admitted" he was correct that using lockdowns to control the spread of COVID-19 was more damaging than the illness.
TriReme Medical, a leading developer of innovative catheters and stents for the treatment of complex vascular disease, announced today the closing of a $17M Round D financing. The financing was led by Bio*One Capital, a subsidiary of Singapore based EDB Investments with strong support from current investors, Three Arch Partners and Adams Street Partners.
The Breast Cancer Research Foundation, announced its dedication of $58.6 million to breast cancer research today at its annual Symposium & Awards Luncheon. Totaling $47 million, the 2014-2015 annual grants, awarded to more than 220 physicians and scientists on six continents, continue to fuel BCRF's mission of advancing the world's most innovative research.
David Allan, Chairman and CEO of YM BioSciences Inc. and Thomas Wellner, President and CEO of Therapure Biopharma Inc. today announced the signing of an agreement under which Therapure Biopharma will provide fill and finish services for nimotuzumab, the humanized monoclonal antibody licensed to YM's majority-owned Canadian subsidiary, CIMYM BioSciences Inc., by the Centre of Molecular Immunology (CIM).
A diagnosis of prostate cancer raises the question for patients and their physicians as to how the tumor will behave. Will it grow quickly and aggressively and require continuous treatment, or slowly, allowing therapy and its risks to be safely delayed?
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Olayinka Adenike Elesha, MD 501 Great Circle Rd, Ste. 200, Nashville, TN 37228-1317 Ph: (615) 222-7685 | Dr Olayinka Adenike Elesha, MD 1700 Medical Center Pkwy, Murfreesboro, TN 37129-2245 Ph: (615) 396-4694 |
News Archive
On Monday, President Donald Trump claimed that the World Health Organization (WHO) "admitted" he was correct that using lockdowns to control the spread of COVID-19 was more damaging than the illness.
TriReme Medical, a leading developer of innovative catheters and stents for the treatment of complex vascular disease, announced today the closing of a $17M Round D financing. The financing was led by Bio*One Capital, a subsidiary of Singapore based EDB Investments with strong support from current investors, Three Arch Partners and Adams Street Partners.
The Breast Cancer Research Foundation, announced its dedication of $58.6 million to breast cancer research today at its annual Symposium & Awards Luncheon. Totaling $47 million, the 2014-2015 annual grants, awarded to more than 220 physicians and scientists on six continents, continue to fuel BCRF's mission of advancing the world's most innovative research.
David Allan, Chairman and CEO of YM BioSciences Inc. and Thomas Wellner, President and CEO of Therapure Biopharma Inc. today announced the signing of an agreement under which Therapure Biopharma will provide fill and finish services for nimotuzumab, the humanized monoclonal antibody licensed to YM's majority-owned Canadian subsidiary, CIMYM BioSciences Inc., by the Centre of Molecular Immunology (CIM).
A diagnosis of prostate cancer raises the question for patients and their physicians as to how the tumor will behave. Will it grow quickly and aggressively and require continuous treatment, or slowly, allowing therapy and its risks to be safely delayed?
› Verified 7 days ago
Peter Meadows, M.D. Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 1700 Medical Center Pkwy, Murfreesboro, TN 37129 Phone: 615-396-4694 Fax: 615-396-6751 | |
Dr. Eva Leinart, MD Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 1700 Medical Center Pkwy, Murfreesboro, TN 37129 Phone: 615-396-4694 | |
Marco A Jarrett, MD Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 820 N Thompson Ln, Suite 1a, Murfreesboro, TN 37129 Phone: 615-494-4800 Fax: 615-494-4801 | |
Diana Constanza Kooper, M.D. Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 1700 Medical Center Pkwy, Murfreesboro, TN 37129 Phone: 615-396-4694 | |
Terrance Matthew Kane, MD Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 1700 Medical Center Pkwy, Murfreesboro, TN 37129 Phone: 615-396-4100 | |
Dr. Montianna S Bingham, MD Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 1700 Medical Center Pkwy, Murfreesboro, TN 37129 Phone: 615-396-4694 Fax: 615-396-6751 |